Please ensure Javascript is enabled for purposes of website accessibility

2 Biotech Stocks Bucking the Trend Right Now

By Cory Renauer – May 18, 2021 at 6:47AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares of these biotechs have been soaring in the opposite direction of their peers.

The SPDR S&P Biotech index, which tracks the world's largest biotech stocks, has lost over a quarter of its value since it peaked in February. Despite an overall stock market that soured on the largest biotech stocks, shares of two have soared.

Just because they're bucking the trend now doesn't necessarily mean they'll keep climbing once they find a way into your portfolio. Have a look at what makes this pair so special before trying to follow their ascent:

Company (Symbol) Gain (Loss) in 2021 Market Cap
BioCryst Pharmaceuticals (BCRX 0.50%) 72% $2.3 billion
Tonix Pharmaceuticals (TNXP -0.35%) 57% $346 million
SPDR S&P Biotech ETF (XBI -0.40%) (-10%) N/A

Data source: Yahoo! Finance.

1. BioCryst Pharmaceuticals

This company focuses on developing new small-molecule drugs that treat rare diseases caused by faulty enzymes. BioCryst made the transition to a commercial-stage business last December when the Food and Drug Administration approved its first drug, Orladeyo, to prevent hereditary angioedema (HAE) attacks.

Bradykinin is an immune-system protein that performs many functions, including dilation of tiny blood vessels at the site of an injury. Production of bradykinin is largely unregulated in HAE patients, which leads to painful, uncontrolled swelling for no good reason. Orladeyo is a once-daily capsule that prevents another enzyme, kallikrein, from producing excess bradykinin.

Smiling scientist holding the eyepieces of a microscope

Image source: Getty Images.

Sales of Orladeyo got off to an encouraging start, producing $11 million in top-line revenue for BioCryst during the first three months of 2021; recent approvals in Europe should accelerate sales before the year's finished.

BioCryst's late-stage development pipeline also includes an orally available treatment for paroxysmal nocturnal hemoglobinuria (PNH) called BCX9930. In the second half of 2021, the company will begin pivotal studies that could make the drug the first needle-free treatment option for this life-threatening blood disorder.

2. Tonix Pharmaceuticals Holding

This clinical-stage drugmaker doesn't have any products it can sell yet, but progress with drugs to address the COVID-19 pandemic keeps driving its stock price to new peaks. Shares of Tonix Pharmaceuticals soared in February after the company reported progress with a potential new COVID-19 skin test. In March, the company also reported positive preclinical data from a study with TNX-1800, a potential coronavirus vaccine.

A new way to test for exposure to SARS-CoV-2 isn't the only new venture Tonix Pharmaceuticals has undertaken this year. In April, the company in-licensed sangivamycin, an experimental antiviral for the potential treatment of COVID-19.

Tonix Pharmaceuticals also has a program in late-stage clinical development for fibromyalgia called TNX-102. Last December, the company showed investors that TNX-102 significantly reduced pain for fibromyalgia patients.

Good stocks to buy now?

Using sales from one drug to try developing lots of new products is fine for commercial-stage businesses. As a clinical-stage company with very limited resources, though, Tonix Pharmaceuticals' unbridled ambition is downright disturbing.

Tonix Pharmaceuticals still hasn't started a clinical trial with its antiviral treatment for COVID-19, so it's going to be a long time before we know if it's worth more than an opportunity to issue a positive-looking press release. Despite plenty of time since its inception, we can say the same for the company's COVID-19 vaccine program.

BioCryst's first drug to earn approval is facing competition from an antibody treatment that's probably more effective. Further ahead, BCX9930 could run into competition from AstraZeneca (AZN -0.54%) and its Soliris/Ultomiris franchise, which the pharmaceutical giant picked up in its recent acquisition of Alexion Pharmaceuticals. But since BioCryst's drug comes in easy-to-swallow capsules, sales will probably be sufficient to fuel the company's effective new drug-discovery engine without tapping investors again.

In addition to having one potential blockbuster on the market and another ready for a pivotal trial, BioCryst appears capable of engineering new small-molecule drugs to fix faulty proteins at will. This is an extremely valuable skill rarely seen among drugmakers with market values as low as BioCryst's right now. That makes BioCryst look like a good stock to buy now and hold on to for the long run.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioCryst Pharmaceuticals Stock Quote
BioCryst Pharmaceuticals
BCRX
$14.14 (0.50%) $0.07
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$56.73 (-0.54%) $0.31
SPDR S&P Biotech Stock Quote
SPDR S&P Biotech
XBI
$82.67 (-0.40%) $0.33
Tonix Pharmaceuticals Holding Stock Quote
Tonix Pharmaceuticals Holding
TNXP
$0.57 (-0.35%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.